The fetus and maternal depression: implications for antenatal treatment guidelines.
The fetus and maternal depression: implications for antenatal treatment guidelines.
复制标题
胎儿和母亲抑郁症：对产前治疗指南的影响。
DOI：
10.1097/01.grf.0000135341.48747.f9
复制
发表时间：
2004
影响因子：
1.5
通讯作者：
Newport,DJeffrey
中科院分区：
文献类型：
--
作者：
Henry,AutumnL;Beach,AquilaJ;Stowe,ZacharyN;Newport,DJeffrey
The conventional package label warning that “use in pregnancy is not recommended unless the potential benefits justify the potential risks to the fetus” is of little value unless those potential benefits and risks are indeed understood. Recognizing the disconnect between such warnings and clinical decision-making, one investigator has argued, with an unmistakable measure of cynicism, that “when manufacturers and official agencies warn against drug treatment during pregnancy, their warnings serve to protect themselves and are of little use to clinically responsible physicians.” 1Indeed, the clinical management of any medical condition during pregnancy is one of relative risk that must consider not only the safety of available treatments but also the potential impact of untreated maternal illness. Ailments such as headaches, nausea, insomnia, and localized infections are routinely treated during pregnancy with a variety of medications that have limited reproductive safety data. Conversely, pregnant women are often advised to discontinue antidepressant medication by physicians and family members alike, despite the rapid accumulation of data regarding the relative safety of antidepressants during gestation. The underlying desire to avoid fetal antidepressant exposure is commendable; however, such recommendations are commonly made with limited understanding of the potential consequences of untreated maternal major depressive disorder (MDD). Comprehensive treatment guidelines for antenatal MDD must therefore incorporate an appraisal of the clinical consequences of fetal exposure to both untreated maternal illness and antidepressant therapy.
